Literature DB >> 19317852

Interleukin-1beta enhances nucleotide-induced and alpha-secretase-dependent amyloid precursor protein processing in rat primary cortical neurons via up-regulation of the P2Y(2) receptor.

Qiongman Kong1, Troy S Peterson, Olga Baker, Emily Stanley, Jean Camden, Cheikh I Seye, Laurie Erb, Agnes Simonyi, W Gibson Wood, Grace Y Sun, Gary A Weisman.   

Abstract

The heterologous expression and activation of the human P2Y(2) nucleotide receptor (P2Y(2)R) in human 1321N1 astrocytoma cells stimulates alpha-secretase-dependent cleavage of the amyloid precursor protein (APP), causing extracellular release of the non-amyloidogenic protein secreted amyloid precursor protein (sAPPalpha). To determine whether a similar response occurs in a neuronal cell, we analyzed whether P2Y(2)R-mediated production of sAPPalpha occurs in rat primary cortical neurons (rPCNs). In rPCNs, P2Y(2)R mRNA and receptor activity were virtually absent in quiescent cells, whereas overnight treatment with the pro-inflammatory cytokine interleukin-1beta (IL-1beta) up-regulated both P2Y(2)R mRNA expression and receptor activity by four-fold. The up-regulation of the P2Y(2)R was abrogated by pre-incubation with Bay 11-7085, an IkappaB-alpha phosphorylation inhibitor, which suggests that P2Y(2)R mRNA transcript levels are regulated through nuclear factor-kappa-B (NFkappaB) signaling. Furthermore, the P2Y(2)R agonist Uridine-5'-triphosphate (UTP) enhanced the release of sAPPalpha in rPCNs treated with IL-1beta or transfected with P2Y(2)R cDNA. UTP-induced release of sAPPalpha from rPCNs was completely inhibited by pre-treatment of the cells with the metalloproteinase inhibitor TACE inhibitor (TAPI-2) or the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, and was partially inhibited by the MAPK/extracellular signal-regulated kinase inhibitor U0126 and the protein kinase C inhibitor GF109203. These data suggest that P2Y(2)R-mediated release of sAPPalpha from cortical neurons is directly dependent on a disintegrin and metalloproteinase (ADAM) 10/17 and PI3K activity, whereas extracellular signal-regulated kinase 1/2 and PI3K activity may indirectly regulate APP processing. These results demonstrate that elevated levels of pro-inflammatory cytokines associated with neurodegenerative diseases, such as IL-1beta, can enhance non-amyloidogenic APP processing through up-regulation of the P2Y(2)R in neurons.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19317852      PMCID: PMC2710802          DOI: 10.1111/j.1471-4159.2009.06048.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  78 in total

Review 1.  Alzheimer's disease pathogenesis and therapeutic interventions.

Authors:  M S Parihar; Taruna Hemnani
Journal:  J Clin Neurosci       Date:  2004-06       Impact factor: 1.961

2.  Processing of amyloid precursor protein in human primary neuron and astrocyte cultures.

Authors:  A C LeBlanc; M Papadopoulos; C Bélair; W Chu; M Crosato; J Powell; C G Goodyer
Journal:  J Neurochem       Date:  1997-03       Impact factor: 5.372

3.  Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity.

Authors:  N Kitaguchi; Y Takahashi; Y Tokushima; S Shiojiri; H Ito
Journal:  Nature       Date:  1988-02-11       Impact factor: 49.962

4.  P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing.

Authors:  Jean M Camden; Ann M Schrader; Ryan E Camden; Fernando A González; Laurie Erb; Cheikh I Seye; Gary A Weisman
Journal:  J Biol Chem       Date:  2005-03-18       Impact factor: 5.157

5.  P2Y2 nucleotide receptor up-regulation in submandibular gland cells from the NOD.B10 mouse model of Sjögren's syndrome.

Authors:  Ann M Schrader; Jean M Camden; Gary A Weisman
Journal:  Arch Oral Biol       Date:  2004-12-15       Impact factor: 2.633

6.  Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain.

Authors:  K Furukawa; B L Sopher; R E Rydel; J G Begley; D G Pham; G M Martin; M Fox; M P Mattson
Journal:  J Neurochem       Date:  1996-11       Impact factor: 5.372

Review 7.  Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease.

Authors:  John B Standridge
Journal:  Curr Alzheimer Res       Date:  2006-04       Impact factor: 3.498

8.  Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain.

Authors:  B Brugg; Y L Dubreuil; G Huber; E E Wollman; N Delhaye-Bouchaud; J Mariani
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration.

Authors:  Solomon S Shaftel; Thaddeus J Carlson; John A Olschowka; Stephanos Kyrkanides; Sarah B Matousek; M Kerry O'Banion
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

10.  Differential brain expression of the Alzheimer's amyloid precursor protein.

Authors:  J P Anderson; L M Refolo; W Wallace; P Mehta; M Krishnamurthi; J Gotlib; L Bierer; V Haroutunian; D Perl; N K Robakis
Journal:  EMBO J       Date:  1989-12-01       Impact factor: 11.598

View more
  32 in total

Review 1.  Supportive or detrimental roles of P2Y receptors in brain pathology?--The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies.

Authors:  Daniel Förster; Georg Reiser
Journal:  Purinergic Signal       Date:  2015-09-25       Impact factor: 3.765

Review 2.  P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential.

Authors:  Gary A Weisman; Lucas T Woods; Laurie Erb; Cheikh I Seye
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-09       Impact factor: 4.388

Review 3.  Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Authors:  Lucas T Woods; Deepa Ajit; Jean M Camden; Laurie Erb; Gary A Weisman
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

Review 4.  P2Y2 nucleotide receptor-mediated responses in brain cells.

Authors:  Troy S Peterson; Jean M Camden; Yanfang Wang; Cheikh I Seye; W G Wood; Grace Y Sun; Laurie Erb; Michael J Petris; Gary A Weisman
Journal:  Mol Neurobiol       Date:  2010-04-13       Impact factor: 5.590

Review 5.  Roles of extracellular nucleotides and P2 receptors in ectodomain shedding.

Authors:  Aleta Pupovac; Ronald Sluyter
Journal:  Cell Mol Life Sci       Date:  2016-05-14       Impact factor: 9.261

Review 6.  P2 receptors for extracellular nucleotides in the central nervous system: role of P2X7 and P2Y₂ receptor interactions in neuroinflammation.

Authors:  Gary A Weisman; Jean M Camden; Troy S Peterson; Deepa Ajit; Lucas T Woods; Laurie Erb
Journal:  Mol Neurobiol       Date:  2012-04-01       Impact factor: 5.590

7.  Loss of P2Y₂ nucleotide receptors enhances early pathology in the TgCRND8 mouse model of Alzheimer's disease.

Authors:  Deepa Ajit; Lucas T Woods; Jean M Camden; Christina N Thebeau; Farid G El-Sayed; Glen W Greeson; Laurie Erb; Michael J Petris; Douglas C Miller; Grace Y Sun; Gary A Weisman
Journal:  Mol Neurobiol       Date:  2013-11-06       Impact factor: 5.590

Review 8.  P2Y receptors in Alzheimer's disease.

Authors:  Laurie Erb; Chen Cao; Deepa Ajit; Gary A Weisman
Journal:  Biol Cell       Date:  2014-10-13       Impact factor: 4.458

9.  Caveolin-1 Regulates the P2Y2 Receptor Signaling in Human 1321N1 Astrocytoma Cells.

Authors:  Namyr A Martinez; Alondra M Ayala; Magdiel Martinez; Freddyson J Martinez-Rivera; Jorge D Miranda; Walter I Silva
Journal:  J Biol Chem       Date:  2016-04-18       Impact factor: 5.157

10.  P2Y2 receptor transcription is increased by NF-kappa B and stimulates cyclooxygenase-2 expression and PGE2 released by intestinal epithelial cells.

Authors:  Emilie Degagné; Djordje M Grbic; Andrée-Anne Dupuis; Elise G Lavoie; Christine Langlois; Nishant Jain; Gary A Weisman; Jean Sévigny; Fernand-Pierre Gendron
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.